Asieris Pharmaceuticals, a global pharma company, announced on Tuesday that it has dosed its first patient in Europe in its multinational, multicentre, Phase III clinical trial (APRICITY) of its photodynamic drug-device combination product APL-1702, Cevira.
The product has been developed as a novel non-surgical treatment of cervical high-grade squamous intraepithelial lesions (HSIL), a pre-cancerous condition caused by a persistent HPV infection.
The study is a multinational, multicentre, randomised, double blind, prospective, placebo-controlled phase III clinical trial to assess the efficacy and safety of APL-1702, Cevira in HSIL. It is an integrated combination of drug and device. Presently, the trial is open for recruitment.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project